Are stimulators of fat oxidation interesting drug discovery targets?
Levens, N.
Current Opinion in Investigational Drugs 6(4): 363
2005
ISSN/ISBN: 1472-4472 PMID: 15898341 Document Number: 593376
Document emailed within 1 workday
Related Documents
Frigeri, A.; Nicchia, G.Paola.; Svelto, M. 2007: Aquaporins as targets for drug discovery Current Pharmaceutical Design 13(23): 2421-2427Hofstadler, S.A.; Griffey, R.H. 2000: Mass spectrometry as a drug discovery platform against RNA targets Current Opinion in Drug Discovery and Development 3(4): 423-431
Zhou, J.; Wild, C. 2019: GPCR Drug Discovery: Emerging Targets, Novel Approaches and Future Trends Current Topics in Medicinal Chemistry 19(16): 1363-1364
Williams, M. 2003: Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia Current Opinion in Investigational Drugs 4(1): 31-36
Kojima, H.; Okabe, T.; Nagano, T. 2013: Open innovation center for drug discovery: a research-supporting network for drug discovery Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 327-332
Fujita, Y. 2013: Innovation by TaNeDS (Take a New challenge of Drug diScovery) collaborative drug discovery project Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(2): 89-95
Shen, Y. 2007: Discovery on Target 2007--CHI's Fifth Annual Conference. RNAi for Drug Discovery and Therapeutics IDrugs: the investigational drugs journal 10(12): 848-850
Young, S.S. 1999: Discovery 99: accelerate and improve the drug discovery process. 26-29 April 1999, San Diego, CA, USA IDrugs: the investigational drugs journal 2(7): 648-649
Tanaka, H. 2013: Search for synapses-forming mechanism for the discovery of therapeutic targets Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(3): 99
Scholl, S.M. 2001: Molecular targets and cancer therapeutics: discovery, biology and clinical applications Idrugs: the Investigational Drugs Journal 4(12): 1357-1360
Scheen, A.J. 1998: Drug clinics. how i treat various metabolic diseases treated by a drug intervention that targets the intestine Revue Medicale de Liege 53(11): 646-650
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Kashyap, A.; Singh, P.Kumar.; Silakari, O. 2018: Counting on Fragment Based Drug Design Approach for Drug Discovery Current Topics in Medicinal Chemistry 18(27): 2284-2293
Barrier, L.; Tallineau, C.; Fauconneau, B.; Piriou, A. 1995: Auto-oxidation or brain homogenate: research of oxidizing agent and targets. Comparison with liver homogenate Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 189(3): 419-428
Emilien, G.; Maloteaux, J.M. 1998: Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities International Journal of Clinical Pharmacology and Therapeutics 36(4): 181-194
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598
Coleman, R. 2018: Setting the scene, setting the targets. The Joint United Nations Programme on HIV/AIDS prevention targets of 2016 and estimating global pre-exposure prophylaxis targets Sexual Health 15(6): 485-488
Bittner, B.; Mountfield, R.J. 2002: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters Current Opinion in Drug Discovery and Development 5(1): 59-71
Bolander, F.F. 2010: Intelligent design: drug targets for the prevention of osteoporosis Current Opinion in Investigational Drugs 11(4): 382-384
Arkhipov, V.I.; Kapralova, M.V. 2011: Metabotropic glutamate receptors as targets for new drug development Eksperimental'naia i Klinicheskaia Farmakologiia 74(10): 46-52